Kidney treatment to prevent CMV virus transmission
Part of Infections clinical trials.
This trial tests a special machine that washes a donated kidney with a drug to remove a common virus called CMV before transplant. It may help prevent the virus from infecting the person who receives the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are on the waiting list for a kidney transplant
- You may or may not have been exposed to CMV in the past
- You are willing to come to follow-up visits
- You are not in other treatment trials
- The donor kidney comes from a deceased person who had the CMV virus
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests two different medication strategies to prevent cytomegalovirus (CMV) infection after a kidney transplant. It compares a plan that uses tacrolimus plus an mTOR inhibitor and only treats if CMV appears, versus a standard plan of tacrolimus plus mycophenolic acid with universal prevention therapy.
Hear when a new Cytomegalovirus (CMV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.